You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Dow
AstraZeneca
Mallinckrodt
Boehringer Ingelheim

Last Updated: October 27, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,653,033

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,653,033 protect, and when does it expire?

Patent 8,653,033 protects PRIALT and is included in one NDA.

This patent has six patent family members in four countries.

Summary for Patent: 8,653,033
Title:Method for administering omega-conopeptide
Abstract: The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the .omega.-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.
Inventor(s): Ellis; David J. (Los Altos, CA), Miljanich; George P. (Redwood City, CA), Shields; David E. (San Lorenzo, CA)
Assignee: Jazz Pharmaceuticals International Limited (Hamilton, BM)
Application Number:13/791,715
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 8,653,033

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Tersera Theraps Llc PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-002 Dec 28, 2004 RX Yes Yes   Start Trial   Start Trial ANALGESIA   Start Trial
Tersera Theraps Llc PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-002 Dec 28, 2004 RX Yes Yes   Start Trial   Start Trial TREATMENT OF PAIN   Start Trial
Tersera Theraps Llc PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-003 Dec 28, 2004 DISCN No No   Start Trial   Start Trial ANALGESIA   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Express Scripts
Medtronic
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.